Insiders Akero Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
19.5 ^USD	+6.44%		-3.18%	-16.49%

May. 15	Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating	MT
May. 10	Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027	MT

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer	Apr. 30	CI
Akero Therapeutics Insider Sold Shares Worth $732,727, According to a Recent SEC Filing	Mar. 07	MT
Akero Therapeutics Insider Sold Shares Worth $2,465,063, According to a Recent SEC Filing	Mar. 07	MT
Akero Therapeutics Insider Bought Shares Worth $1,982,940, According to a Recent SEC Filing	Dec. 12	MT
Akero Therapeutics Insider Sold Shares Worth $1,197,827, According to a Recent SEC Filing	23-10-05	MT
Akero Therapeutics Insider Sold Shares Worth $1,244,248, According to a Recent SEC Filing	23-09-19	MT
Insider Buy: Akero Therapeutics	23-08-10	MT
Insider Sell: Akero Therapeutics	23-08-03	MT
Insider Buy: Akero Therapeutics	23-08-02	MT
Insider Sell: Akero Therapeutics	23-07-07	MT
Insider Sell: Akero Therapeutics	23-06-26	MT
Insider Sell: Akero Therapeutics	23-06-21	MT
Insider Sell: Akero Therapeutics	23-06-21	MT
Insider Sell: Akero Therapeutics	23-06-21	MT
Insider Sell: Akero Therapeutics	23-06-06	MT
Insider Sell: Akero Therapeutics	23-05-04	MT
Insider Sell: Akero Therapeutics	23-03-03	MT
Insider Sell: Akero Therapeutics	23-02-03	MT
Insider Sell: Akero Therapeutics	23-01-18	MT
Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy	23-01-10	CI

No results for this search